Synaptogenix, Inc. (NASDAQ:SNPX) Sees Significant Decline in Short Interest

Synaptogenix, Inc. (NASDAQ:SNPX) saw a significant decline in short interest in February. As of February 28th, there was short interest totalling 21,800 shares, a decline of 26.8% from the February 13th total of 29,800 shares. Based on an average daily volume of 15,000 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.6% of the shares of the stock are sold short.

Synaptogenix Trading Down 6.2 %

Shares of SNPX stock traded down $0.18 during trading hours on Friday, hitting $2.72. The company had a trading volume of 4,473 shares, compared to its average volume of 12,095. Synaptogenix has a 12 month low of $2.32 and a 12 month high of $6.22. The firm’s fifty day moving average is $3.12 and its 200 day moving average is $3.08.

Institutional Trading of Synaptogenix

An institutional investor recently bought a new position in Synaptogenix stock. Geode Capital Management LLC bought a new stake in Synaptogenix, Inc. (NASDAQ:SNPX) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned approximately 0.80% of Synaptogenix as of its most recent filing with the SEC. Institutional investors own 10.34% of the company’s stock.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.